An Update on Randomized Clinical Trials in Hepatocellular Carcinoma

Hao-Wen Sim; Jennifer Knox; Laura A Dawson

doi:10.1016/j.soc.2017.05.006

An Update on Randomized Clinical Trials in Hepatocellular Carcinoma

Surg Oncol Clin N Am. 2017 Oct;26(4):647-666. doi: 10.1016/j.soc.2017.05.006. Epub 2017 Aug 4.

Authors

Hao-Wen Sim¹, Jennifer Knox¹, Laura A Dawson²

Affiliations

¹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
² Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada. Electronic address: Laura.Dawson@rmp.uhn.on.ca.

PMID: 28923223
DOI: 10.1016/j.soc.2017.05.006

Abstract

Hepatocellular carcinoma is a common malignancy that typically occurs in the setting of comorbid liver disease. Optimal management is challenging, especially given the assortment of available treatment modalities. This article reviews the randomized clinical trials that have formed the basis of contemporary hepatocellular carcinoma management.

Keywords: Evidence-based medicine; Hepatocellular carcinoma; Management; Randomized trials; Review.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoma, Hepatocellular / therapy*
Humans
Liver Neoplasms / therapy*
Randomized Controlled Trials as Topic*
Treatment Outcome

Substances

Antineoplastic Agents